MindBio Therapeutics (MBIO) Stock Overview
Operates as a clinical stage drug development company in Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
MindBio Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.01 |
| 52 Week High | CA$0.035 |
| 52 Week Low | CA$0.005 |
| Beta | -0.37 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -60.00% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBIO | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 100.0% | 16.5% | 1.6% |
| 1Y | -60.0% | -13.6% | 22.2% |
Return vs Industry: MBIO underperformed the Canadian Pharmaceuticals industry which returned -13.6% over the past year.
Return vs Market: MBIO underperformed the Canadian Market which returned 22.2% over the past year.
Price Volatility
| MBIO volatility | |
|---|---|
| MBIO Average Weekly Movement | 102.8% |
| Pharmaceuticals Industry Average Movement | 12.9% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 19.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MBIO's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MBIO's weekly volatility has increased from 83% to 103% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Justin Hanka | www.mindbiotherapeutics.com |
MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain.
MindBio Therapeutics Corp. Fundamentals Summary
| MBIO fundamental statistics | |
|---|---|
| Market cap | CA$6.85m |
| Earnings (TTM) | -CA$1.50m |
| Revenue (TTM) | n/a |
Is MBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBIO income statement (TTM) | |
|---|---|
| Revenue | -AU$630.65k |
| Cost of Revenue | AU$0 |
| Gross Profit | -AU$630.65k |
| Other Expenses | AU$1.00m |
| Earnings | -AU$1.63m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0024 |
| Gross Margin | 100.00% |
| Net Profit Margin | 258.71% |
| Debt/Equity Ratio | -82.0% |
How did MBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 16:09 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MindBio Therapeutics Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.